Acumen Pharmaceuticals: Altitude-AD Failure Destroys The Investment Thesis (Rating Downgrade)
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer’s Data Approach
Acumen Pharmaceuticals (NASDAQ:ABOS) Narrows Q3 Loss as ALTITUDE-AD Readout Looms
Loading...